Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 plus dabrafenib and trametinib versus placebo plus dabrafenib and trametinib in untreated BRAF V600-mutant unresectable or metastatic melanoma
NL-OMON54792Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of spartalizumab, dabrafenib + trametinib, trametinib in melanoma, sponsored by Novartis. Started Dec 2017; status: active, not recruiting.
02
Drugs
spartalizumabdabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON54792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54792.